Compare · MDLN vs NVRO
MDLN vs NVRO
Side-by-side comparison of Medline Inc. (MDLN) and Nevro Corp. (NVRO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and NVRO operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.08B, about 22.3x NVRO ($2.15B).
- MDLN has hit the wire 7 times in the past 4 weeks while NVRO has been quiet.
- Both have 25 recent analyst ratings on file.
- Company
- Medline Inc.
- Nevro Corp.
- Price
- $35.95-1.74%
- $5.84+0.00%
- Market cap
- $48.08B
- $2.15B
- 1M return
- +11.97%
- -
- 1Y return
- -11.77%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- 2014
- News (4w)
- 7
- 0
- Recent ratings
- 25
- 25
Nevro Corp.
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. In addition, the company provides HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M
Latest NVRO
- SEC Form 15-12G filed by Nevro Corp.
- SEC Form EFFECT filed by Nevro Corp.
- Amendment: SEC Form SCHEDULE 13D/A filed by Nevro Corp.
- Director Mccormick Shawn returned 46,035 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Kosaraju Sridhar returned 46,575 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Grossman D Keith returned 228,552 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SVP, Chief Financial Officer Macleod Roderick H. returned 350,663 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Demane Michael F returned 503,618 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Karros Kirt P returned 17,452 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Oboyle Kevin C returned 43,396 shares to the company, closing all direct ownership in the company (SEC Form 4)